tetano
Editor, Senior Moderator
Nat Commun
. 2022 Nov 3;13(1):6602.
doi: 10.1038/s41467-022-34521-0.
A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
Atsuhiro Yasuhara[SUP] 1 [/SUP], Seiya Yamayoshi[SUP] 2 3 4 [/SUP], Maki Kiso[SUP] 1 [/SUP], Yuko Sakai-Tagawa[SUP] 1 [/SUP], Moe Okuda[SUP] 1 [/SUP], Yoshihiro Kawaoka[SUP] 5 6 7 8 [/SUP]
Affiliations
Abstract
Improved vaccines and antiviral agents that provide better, broader protection against seasonal and emerging influenza viruses are needed. The viral surface glycoprotein hemagglutinin (HA) is a primary target for the development of universal influenza vaccines and therapeutic antibodies. The other major surface antigen, neuraminidase (NA), has been less well studied as a potential target and fewer broadly reactive anti-NA antibodies have been identified. In this study, we isolate three human monoclonal antibodies that recognize NA from A/H1N1 subtypes, and find that one of them, clone DA03E17, binds to the NA of A/H3N2, A/H5N1, A/H7N9, B/Ancestral-lineage, B/Yamagata-lineage, and B/Victoria-lineage viruses. DA03E17 inhibits the neuraminidase activity by direct binding to the enzyme active site, and provides in vitro and in vivo protection against infection with several types of influenza virus. This clone could, therefore, be useful as a broadly protective therapeutic agent. Moreover, the neutralizing epitope of DA03E17 could be useful in the development of an NA-based universal influenza vaccine.
. 2022 Nov 3;13(1):6602.
doi: 10.1038/s41467-022-34521-0.
A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
Atsuhiro Yasuhara[SUP] 1 [/SUP], Seiya Yamayoshi[SUP] 2 3 4 [/SUP], Maki Kiso[SUP] 1 [/SUP], Yuko Sakai-Tagawa[SUP] 1 [/SUP], Moe Okuda[SUP] 1 [/SUP], Yoshihiro Kawaoka[SUP] 5 6 7 8 [/SUP]
Affiliations
- PMID: 36329075
- DOI: 10.1038/s41467-022-34521-0
Abstract
Improved vaccines and antiviral agents that provide better, broader protection against seasonal and emerging influenza viruses are needed. The viral surface glycoprotein hemagglutinin (HA) is a primary target for the development of universal influenza vaccines and therapeutic antibodies. The other major surface antigen, neuraminidase (NA), has been less well studied as a potential target and fewer broadly reactive anti-NA antibodies have been identified. In this study, we isolate three human monoclonal antibodies that recognize NA from A/H1N1 subtypes, and find that one of them, clone DA03E17, binds to the NA of A/H3N2, A/H5N1, A/H7N9, B/Ancestral-lineage, B/Yamagata-lineage, and B/Victoria-lineage viruses. DA03E17 inhibits the neuraminidase activity by direct binding to the enzyme active site, and provides in vitro and in vivo protection against infection with several types of influenza virus. This clone could, therefore, be useful as a broadly protective therapeutic agent. Moreover, the neutralizing epitope of DA03E17 could be useful in the development of an NA-based universal influenza vaccine.